Cost-effectiveness analysis of guidelines for antihypertensive care in Finland

BMC Health Services Research

Volumn 7, Issue , 2007, Pages

  Booth, Neill ^a   Jula, Antti ^b   Aronen, Pasi ^b,c   Kaila, Minna ^b,d   Klaukka, Timo ^e   Kukkonen Harjula, Katriina ^f   Reunanen, Antti ^b   Rissanen, Pekka ^a   Sintonen, Harri ^b,c   Mäkelä, Marjukka ^b,g  

^a UNIVERSITY OF TAMPERE   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e SOCIAL INSURANCE INSTITUTION   (Finland)

^f UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; METOPROLOL; NIFEDIPINE; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; FEMALE; FINLAND; FUNCTIONAL STATUS; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL MODEL; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG ADMINISTRATION; DRUG UTILIZATION; ECONOMICS; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; REGISTER; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; FINLAND; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES;

EID: 37849030998     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-7-172     Document Type: Article

References (65)

1. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. MM Ortegon WK Redekop LW Niessen, Diabetes Care 2004 27 901 907 10.2337/diacare.27.4.901 15047646
2. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. C Issakidis K Sanderson J Corry G Andrews H Lapsley, Psychol Med 2004 34 19 35 10.1017/S003329170300881X 14971624
3. Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective? BM Spiegel L Targownik GS Dulai HA Karsan IM Gralnek, Hepatology 2003 37 366 377 10.1053/jhep.2003.50050 12540787
4. Evaluation of the relative cost-effectiveness of treatments for infertility in the UK. Z Philips M Barraza-Llorens J Posnett, Hum Reprod 2000 15 95 106 10.1093/humrep/15.1.95 10611196
5. Cost effectiveness of combination HIV therapy: 3 years later. RD Moore, Pharmacoeconomics 2000 17 325 330 10.2165/00019053-200017040-00002 10947487
6. The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis. CR Macintyre AJ Plant D Hendrie, Health Econ 2000 9 411 421 10.1002/1099-1050(200007)9:5<411::AID-HEC524>3. 0.CO;2-9 10903541
7. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. WJ Elliott DR Weir HR Black, Arch Intern Med 2000 160 1277 1283 10.1001/archinte.160.9.1277 10809030
8. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. SD Ramsey N Neil SD Sullivan E Perfetto, J Am Board Fam Pract 1999 12 105 114 10220232
9. Cost-effectiveness analysis of lead poisoning screening strategies following the 1997 guidelines of the Centers for Disease Control and Prevention. AR Kemper WC Bordley SM Downs, Arch Pediatr Adolesc Med 1998 152 1202 1208 9856430
10. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. J Cromwell WJ Bartosch MC Fiore V Hasselblad T Baker, Jama 1997 278 1759 1766 10.1001/jama.278.21.1759 9388153
11. Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice. G Richardson L Godfrey H Gravelle I Watt, Br J Gen Pract 2004 54 765 771 15469676
12. Hypertension: a Policy Perspective. MC Weinstein WB Stason, Cambridge, Harvard University Press 1976
13. Moderately elevated blood pressure. Swedish Council on Technology Assessment in Health Care (SBU), J Intern Med Suppl 1995 737 1 225 9043531
14. Cost-effectiveness of antihypertensive treatment. General considerations. LB Russell, Hypertension 1989 13 I141 4 2577458
15. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JT Edelson MC Weinstein AN Tosteson L Williams TH Lee L Goldman, Jama 1990 263 407 413 10.1001/jama.263.3.407 2136759
16. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). M Johannesson B Dahlof LH Lindholm T Ekbom L Hansson A Oden B Schersten PO Wester B Jonsson, J Intern Med 1993 234 317 323 8354983
17. Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics. M Johannesson J Wikstrand B Jonsson G Berglund J Tuomilehto, Pharmacoeconomics 1993 3 36 44 10146986
18. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. M Johannesson, Health Policy 1994 28 1 13 10.1016/0168-8510(94)90016-7 10136603
19. The cost effectiveness of hypertension treatment in Sweden. M Johannesson, Pharmacoeconomics 1995 7 242 250 10155314
20. Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. F Andersson B Kartman OK Andersson, Clin Exp Hypertens 1998 20 833 846 9817605
21. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Mar F Rodriguez-Artalejo, J Hypertens 2001 19 149 155 10.1097/00004872-200101000-00020 11204296
22. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. AA Montgomery T Fahey Y Ben-Shlomo J Harding, Journal of Hypertension 2003 21 1753 1759 10.1097/00004872-200309000-00026 12923409
23. [Treatment of hypertension]. [Finnish Hypertension Society's task force], Duodecim 2002 118 110 126 12228989
24. Multiple clinic and home blood pressure measurements versus ambulatory blood pressure monitoring. A Jula P Puukka H Karanko, Hypertension 1999 34 261 266 10454451
25. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. D Wood G De Backer O Faergeman I Graham G Mancia K Pyörälä Eur Heart J 1998 19 1434 1503 10.1053/euhj.1998.1243 9820987
26. TreeAge Pro (2006). Williamstown, MA: TreeAge Software, Inc. TreeAge Software, 2006
27. Annex to the decree of the Ministry of Social Affairs and Health concerning the Health Insurance Act. 2003
28. The 15D instrument of health-related quality of life: properties and applications. H Sintonen, Ann Med 2001 33 328 336 11491191
29. A Language and Environment for Statistical Computing. R Development Core Team, R Foundation for Statistical Computing 2005
30. SAS user's guide, version 6.12. Cary, NC: SAS Institute, Inc. SAS Institute, 1996
31. Health and functional capacity in Finland: baseline results of the Health 2000 health examination survey. A Aromaa S Koskinen, Helsinki, Publications of the National Public Health Institute, B12, Aromaa AKS, 2004
32. An updated coronary risk profile: a statement for health professionals. KM Anderson PW Wilson PM Odell WB Kannel, Circulation 1991 83 356 362 1984895
33. Terveys, toimintakyky ja hoidontarve Suomessa. Mini-Suomi- terveystutkimuksen perustulokset (Health, functional limitations, and need for care in Finland: basic results from the Mini-Finland Health Survey, in Finnish with an English summary). A Aromaa M Heliövaara O Impivaara P Knekt J Maatela M Joukamaa T Klaukka V Lehtinen T Melkas E Mälkiä K Nyman I Paunio A Reunanen K Sievers E Kalimo V Kallio, English summary: Health, functional limitations and need for care in Finland Basic results from the Mini-Finland Health Survey Helsinki and Turku, Publications of the Social Insurance Institution, AL:32 1989 792
34. Markov models in medical decision making: a practical guide. FA Sonnenberg JR Beck, Med Decis Making 1993 13 322 338 10.1177/0272989X9301300409 8246705
35. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. S MacMahon R Peto J Cutler R Collins P Sorlie J Neaton R Abbott J Godwin A Dyer J Stamler, Lancet 1990 335 765 774 10.1016/0140-6736(90)90878-9 1969518
36. [Guidelines for health care unit costs in Finland 2003]. T Hujanen, National Research and Development Centre for Welfare and Health (STAKES), Helsinki Aiheita 1/2003
37. Non-pharmacological treatment of hypertension in primary health care: a 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. MJ Kastarinen PM Puska MH Korhonen JN Mustonen VV Salomaa JE Sundvall JO Tuomilehto MI Uusitupa AM Nissinen, J Hypertens 2002 20 2505 2512 10.1097/00004872-200212000-00031 12473876
38. Financial and health costs of uncontrolled blood pressure in the United Kingdom. A Lloyd C Schmieder N Marchant, Pharmacoeconomics 2003 21 Suppl. 1 33 41 10.2165/00019053-200321001-00004 12648033
39. Reimbursement of medicine costs: a glossary. [accessed 12.07.2006]. The Social Insurance Institution of Finland, http://www.kela.fi/in/internet/english/ english.nsf/NET/220703141254MP
40. Non-pharmacological treatment of hypertension in primary health care: a 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. MJ Kastarinen PM Puska MH Korhonen JN Mustonen VV Salomaa JE Sundvall JO Tuomilehto MI Uusitupa AM Nissinen, J Hypertens 2002 20 2505 2512 10.1097/00004872-200212000-00031 12473876
41. Comparisons of hypertension-related costs from multinational clinical studies. CD Mullins M Sikirica V Seneviratne J Ahn KS Akhras, Pharmacoeconomics 2004 22 1001 1014 10.2165/00019053-200422150-00004 15449964
42. Cardiovascular disease costs associated with uncontrolled hypertension. JM Flack R Casciano J Casciano J Doyle S Arikian S Tang R Arocho, Manag Care Interface 2002 15 28 36 12449899
43. Costs of coronary heart disease and stroke: the case of Sweden. N Zethraeus T Molin P Henriksson B Jonsson, JInternMed 1999 246 151 159
44. Measurement of health outcome and associated costs in cardiovascular disease. B Jonsson, EurHeart J 1996 17 Suppl A 2 7
45. Direct medical costs of coronary artery disease in the United States. MW Russell DM Huse S Drowns EC Hamel SC Hartz, Am J Cardiol 1998 81 1110 1115 10.1016/S0002-9149(98)00136-2 9605051
46. Interventions used to improve control of blood pressure in patients with hypertension. T Fahey K Schroeder S Ebrahim, Cochrane Database Syst Rev 2006 CD005182
47. Primer on medical decision analysis: Part 4 - Analyzing the model and interpreting the results. MD Krahn G Naglie D Naimark DA Redelmeier AS Detsky, Med Decis Making 1997 17 142 151 10.1177/0272989X9701700204 9107609
48. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. MR Law NJ Wald JK Morris RE Jordan, BMJ 2003 326 1427 1434 12829555 10.1136/bmj.326.7404.1427
49. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Canadian Agency for Drugs and Technologies in Health, 2006
50. The CE plane: a graphic representation of cost-effectiveness. WC Black, Med Decis Making 1990 10 212 214 10.1177/0272989X9001000308 2115096
51. Use and misuse of the term "cost effective" in medicine. P Doubilet MC Weinstein BJ McNeil, N Engl J Med 1986 314 253 256 3079883
52. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. FM Sacks LP Svetkey WM Vollmer LJ Appel GA Bray D Harsha E Obarzanek PR Conlin ER Miller 3rd DG Simons-Morton N Karanja PH Lin, N Engl J Med 2001 344 3 10 10.1056/NEJM200101043440101 11136953
53. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. AM Jula HM Karanko, Circulation 1994 89 1023 1031 8124787
54. Long-term nopharmacological treatment for mild to moderate hypertension. A Jula T Ronnemaa M Rastas RL Karvetti J Maki, J Intern Med 1990 227 413 421 2191071
55. English summary of the 2005-updated Hypertension Current Care guideline. Editors, Current Care Summaries http://www.kaypahoito.fi/kh/kaypahoito?suositus= ccs00014
56. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. A Fretheim M Aaserud AD Oxman, BMC Health Serv Res 2003 3 18 12959644 10.1186/1472-6963-3-18
57. Hypertension: management of hypertension in adults in primary care: partial update. National Collaborating Centre for Chronic Conditions, 2006
58. Routinely collected registers in Finnish health research. M Gissler, Statistics, registries, and science - experiences from Finland Keuruu, Statistics Finland, Alho J, 1999 241-54
59. Accuracy of data on diagnoses, procedures and accidents in the Finnish Hospital Discharge Register. I Keskimäki S Aro, Internal Journal of Health Sciences 1991 2 15 21
60. Clinical practice guidelines and organizational adaptation: a framework for analyzing economic effects. JE Schneider NA Peterson TE Vaughn EN Mooss BN Doebbeling, Int J Technol Assess Health Care 2006 22 58 66 16673681
61. Cost-effectiveness in health and medicine. MR Gold JE Siegel LB Russell MC Weinstein, Oxford, Oxford University Press 1996
62. Long-term cost and life-expectancy consequences of hypertension. U Kiiskinen E Vartiainen P Puska A Aromaa, Journal of Hypertension 1998 16 1103 1112 10.1097/00004872-199816080-00004 9794712
63. Modelling in the economic evaluation of health care: selecting the appropriate approach. P Barton S Bryan S Robinson, J Health Services Research and Health Policy 2004 8 110 118 10.1258/135581904322987535
64. Towards the equitably efficient and transparently decidable use of public funds in the deep blue millennium. J Dowie, Health Econ 1998 7 93 103 10.1002/(SICI)1099-1050(199803)7:2<93::AID-HEC313>3.0.CO;2-2 9565166
65. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? S Birch A Gafni, J Health Econ 1992 11 279 296 10.1016/0167-6296(92)90004-K 10122540